What does the evidence show about Dulaglutide's effects?

Read Off Label rates the evidence for Dulaglutide as Strong and the benefit magnitude as med, producing an overall grade of B (6.4/10). Primarily a diabetes drug — weight loss effect less than semaglutide/tirzepatide (~3-5%).

What safety findings are reported for Dulaglutide?

Dulaglutide has a med risk profile in the database. Med Legal status: Rx.

Rankings / Metabolic Health

Dulaglutide

Metabolic Health · GLP-1 agonist

Also known as: Trulicity

Tier B

Reviewed by Read Off Label · Last reviewed Jul 11, 2026 · How we grade

glp-1methylationprescription

6.4 / 10

Tier B

Ev 8 Bn 5 Sf 5

Bottom line

Read Off Label grades Dulaglutide as B (6.4/10) based on strong evidence, med benefit magnitude, and a med-risk safety profile.

Primarily a diabetes drug — weight loss effect less than semaglutide/tirzepatide (~3-5%).

Studied, labeled, or reported-use context: Trulicity: 0. — Rx; not individualized guidance.

What the evidence says

Primarily a diabetes drug — weight loss effect less than semaglutide/tirzepatide (~3-5%). REWIND trial: 12% MACE reduction in broad T2D population. Primary place is T2D management not obesity pharmacotherapy.

Mechanism

Weekly GLP-1 receptor agonist; same mechanism as semaglutide; approved primarily for T2D

Studied, labeled, or reported dose & route

Trulicity: 0.75-4.5 mg SC weekly

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Dulaglutide's effects?: Read Off Label rates the evidence for Dulaglutide as Strong and the benefit magnitude as med, producing an overall grade of B (6.4/10). Primarily a diabetes drug — weight loss effect less than semaglutide/tirzepatide (~3-5%).
What safety findings are reported for Dulaglutide?: Dulaglutide has a med risk profile in the database. Med Legal status: Rx.
What doses or routes are reported for Dulaglutide?: Trulicity: 0.75-4.5 mg SC weekly This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Dulaglutide work?: Weekly GLP-1 receptor agonist; same mechanism as semaglutide; approved primarily for T2D

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.